Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Davis Fundamental ETF Trust Davis Select U.S. Equity ETF
(BATS:DUSA)
Intraday
$39.09
0.31
[0.80%]
Get Report
Watch
Perks
Buy
Compare Brokers
$39.09
0.31
[0.80%]
At close: Apr 26
Get Report
Watch
Overview
News
Dividends
Short Interest
Latest News for Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS:DUSA)
Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS: DUSA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Sunday, January 19, 2020
4 ETFs For Alphabet's Ascent Into The Four Comma Club
ETF Professor
-
Jan 19, 2020, 2:34PM
Wednesday, April 12, 2017
A Solid Start For A New Active ETF
Benzinga
-
Apr 12, 2017, 11:12AM
Monday, December 17, 2012
C.K. Cooper & Company Reiterates Buy on DUSA Pharmaceuticals, Inc., Maintains $9.50 PT
Benzinga
-
Dec 17, 2012, 12:49PM
Wednesday, December 05, 2012
Caraco, DUSA Pharma Announce Early Termination of Hart-Scott-Rodino Waiting Period for Tender Offer
Benzinga
-
Dec 5, 2012, 12:01PM
Thursday, November 08, 2012
Shares of DUSA Pharma Up 38+% Following $8/Share Bid from Sun Pharma
Benzinga
-
Nov 8, 2012, 7:54AM
Thursday, September 13, 2012
DUSA Pharma Says Positive Results in Phase 2 Actinic
Benzinga
-
Sep 13, 2012, 6:32AM
Thursday, August 02, 2012
Dusa Pharmaceuticals Reports Q2 EPS $0.06 vs $0.06 Est; Revenues $11.7M vs $11.85M Est
Benzinga
-
Aug 2, 2012, 8:42AM
Dusa Pharmaceuticals Reports Q2 EPS $0.06 vs $0.06 Est; Revenues $11.7M vs $11.85M Est
Benzinga
-
Aug 2, 2012, 6:45AM
Tuesday, May 08, 2012
Dusa Pharmaceuticals Reports Q1 EPS $0.08 vs $0.07 Est; Revenues $13.4M vs $12.92M Est
Benzinga
-
May 8, 2012, 6:45AM
Tuesday, April 24, 2012
DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan Kerastick Photodynamic Therapy
Benzinga
-
Apr 24, 2012, 7:35AM
Tuesday, March 06, 2012
UPDATE: C.K. Cooper Initiates Coverage on DUSA Pharmaceuticals
Benzinga
-
Mar 6, 2012, 7:18AM
CK Cooper Initiates Coverage on Dusa Pharmaceuticals at Buy, Announces PT of $8
Benzinga
-
Mar 6, 2012, 5:59AM
Tuesday, January 31, 2012
Potential Trades This Week: Looking For Consolidation
Benzinga
-
Jan 31, 2012, 12:38AM
Sunday, January 29, 2012
Weekly Traders Homework: Frustrated Bears
Benzinga
-
Jan 29, 2012, 8:15PM
Monday, June 27, 2011
DUSA Pharmaceuticals Added to Russell 3000 Index
Benzinga
-
Jun 27, 2011, 7:31AM
Friday, May 06, 2011
Preventing the Most Common Form of Cancer (DUSA)
Benzinga
-
May 6, 2011, 2:23PM
Preventing the Most Common Form of Cancer (DUSA)
Benzinga
-
May 6, 2011, 2:23PM
Thursday, May 05, 2011
Top Percentage Gainers and Losers as of 2pm 04/05/11 (KNDL, DUSA, ROCK, PPO, BDCO, MW, FONR, LEAP, TBL, SCEI, SMSI, SVNT, GLBL, DEER, UDRL, ARO)
Benzinga
-
May 5, 2011, 2:05PM
Top Percentage Gainers and Losers as of 12pm 04/05/11 (KNDL, PPO, DUSA, ROCK, SHS, TBL, SMSI, ARO, SCEI, SVNT)
Benzinga
-
May 5, 2011, 11:58AM
Friday, March 25, 2011
DUSA Pharmaceuticals Up Almost 8% (DUSA)
Benzinga
-
Mar 25, 2011, 12:26PM
Monday, March 14, 2011
(DUSA) Keep an Eye on (DUSA) Above $4.42 great breakout on charts
Benzinga
-
Mar 14, 2011, 2:52PM
Thursday, March 03, 2011
NASDAQ Stocks Hitting 52-Week Highs (GTEC, SIMO, ERIC, DUSA)
Benzinga
-
Mar 3, 2011, 10:10AM
Morning Market Movers (GTEC, ASGR, LSBK, DUSA)
Benzinga
-
Mar 3, 2011, 9:57AM
Dusa Pharmaceuticals Reports Q4 EPS of $0.12
Benzinga
-
Mar 3, 2011, 6:48AM